Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75p -2.86% 25.50p 25.00p 26.00p 26.25p 25.50p 26.25p 337,368 11:00:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 64.1 -2.0 -0.4 - 154.05

Allergy Therapeutics Share Discussion Threads

Showing 3526 to 3549 of 3550 messages
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
22/5/2018
18:57
Some good info in this interview. Must admit that I thought they would be in to the phase 3 program earlier than the Q3 2019 recruitment date stated. Huge opportunity though and the barriers to entry for others will be high so a little more patience required.
audigger
22/5/2018
18:51
Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018
gersemi
22/5/2018
13:16
Afternoon, Short TV interview with both CEO Manuel Llobet and House broker Panmure Gordon's Healthcare Analyst Dr Mike Mitchell www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
oshy92
21/5/2018
09:42
Agreed, I trade ranges which means I almost always sell out too soon! Still, it's putting bread on the table and I'm long term on a couple of favourites. Must admit I like the story here, will be watching closely.
rathean
21/5/2018
09:30
I use to regularly buy and sell these but some day soon it will take off so now I just buy the dips. That said I recently sold a number of other shares which I made money on but have absolutely flown since I sold! Such is investing. A profit is a profit! Will get the Ferrari when they hit 100p!
audigger
21/5/2018
09:12
That's me out with a rather pleasant 10% gain. Very positive news though, will be back in when the price is right, gla.
rathean
21/5/2018
08:41
You could upgrade to a Ferrari at this rate!
richsawko
21/5/2018
08:28
Well there's some proof of concept for you! Looks like I timed my top-up well for once. I'm tempted to add more but spare cash is heading for a car purchase!
audigger
21/5/2018
08:28
WOW 2.5M trade!
richsawko
21/5/2018
08:00
Excellent announcement today looking positive for the future of this company
richsawko
18/5/2018
09:20
Thanks gold digger, I like the story here and their revenue numbers despite a low pollen season last year are impressive. Took a nibble a few days ago.
rathean
16/5/2018
14:33
We're still a way off having proof of concept from pivotal studies, hence a study in transgenic mice isn't going to lift the share price I've added another chunk today which means that this is approaching my largest single holding. I never look at technical analysis on early stage life science shares; they are somewhat meaningless. Good news from clinical trials and this will fly. Of course the converse is also true hence a moderately risky play. Management team seem impressive and they have a variety of technologies either one of which could be a commercial success.
audigger
15/5/2018
09:48
So why the steep falling channel and no uplift on good clinical data?
rathean
14/5/2018
16:57
Looks like this article has prompted today's rise: Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology Novel Findings Further Highlight the Effectiveness of MCT as Alternative to Alum and its Potential Advantage in Allergy-Specific Immunotherapy WORTHING, United Kingdom, 14 May 2018 - Allergy Therapeutics (AIM:AGY), a leading, fully-integrated commercial biotechnology company specialising in allergy vaccines, today announces that new data from a study investigating immune responses produced by microcrystalline tyrosine (MCT®)-based vaccines as compared with conventional aluminium hydroxide has been published online in The Journal of Immunology. The findings demonstrate that, based on its comparable strength and mechanism of Ag-specific IgG induction and induction of T cell responses, MCT® is a suitable and flexible alternative to aluminium hydroxide as an adjuvant in both allergen-specific immunotherapy and infectious disease applications. The study also demonstrated that MCT®-adjuvanted allergens caused fewer anaphylactic reactions compared with alum-adjuvanted allergens. "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines," said Matthias Kramer, M.D., Allergy Therapeutics' International Medical Director and co-author of the paper. "We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines." This is the first study to report the mechanism of action by which MCT governs the immunologic response after exposure to an antigen and protection against anaphylaxis in an allergic model. The results illustrate upregulation of IgG antibody responses and a higher IgE:IgG ratio in MCT-based immunotherapy compared with Alum-based immunotherapy. A high IgE:IgG ratio has been reported to be a positive predictive marker for allergen immunotherapy in humans. Further evaluation in this study indicated that MCT facilitates robust adaptive T cell responses with associated IFN-γ (interferon gamma) and TNF-α (tumour necrosis factor alpha), which is in line with previous studies illustrating protective efficacy in influenza and malaria applications1, 2. Meanwhile, studies in a cancer (melanoma) model are underway. A link to publication is here: www.jimmunol.org/content/200/9/3151
audigger
04/5/2018
15:26
New low for the year! :(
jpuff
25/4/2018
19:09
"IF" the trials are seen as successful, it will be a real riot if they are not!
jimmyloser
25/4/2018
18:43
Agreed, worked out my average purchase price of my accumulated holdings to be 12.7p, looking, like many, for 100p. I predict a riot when the trials are seen as successful DYOR/IMHO
aruntim
12/4/2018
21:56
The potential upside remains significant IMO. Thus share has a pattern of making quicknrises then slowly drifting back over time. I guess ones ability to tolerate this depends on your entry point. Anyone who bought in above 30p will be feeling bad about nursing some paper losses. H2 2018 looks to be the start of a key period of news flow. I'm optimistic we may end the year around 40p so long as the US opportunity remains on track. My personal target is to sell these at 100p within the next 5-10 years.
audigger
12/4/2018
10:51
I wouldn't let these go for love nor money! Others might have a confidence issue, I certainly don't! Withy Allergy they can RNS something positive at any time!
jimmyloser
12/4/2018
10:35
Maybe if there's a general lack of confidence we should be holding something else! Too late for me now as I'm well under water here now :(
jpuff
12/4/2018
09:51
Yes, it is just due to lack of confidence. They are prone to setbacks. Peeps are waiting for the outcome of the trials. As the company said themselves this is a transitional year! impo/dyor
jimmyloser
12/4/2018
09:07
What is happening to these shares, now at a year low!
richsawko
15/3/2018
12:22
The video from last week's Shares Mag presentation is now available: https://www.sharesmagazine.co.uk/video/nick-wykeman-fd-allergy-therapeutics-agy
timbo003
08/3/2018
10:23
If they get a positive result on the two trials, this will (impo) fly past 40p in a re-rating. However if they don't???? Too cheap right now. dyor impo
jimmyloser
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180526 19:46:30